Optics11 Life is excited to announce that we have successfully raised $17,000,000 in our latest funding round—a testament to our breakthrough technology and the growing recognition of its potential within the scientific community. Since our founding in 2011, we have been driven by the belief that every cell and tissue tells a unique story of mechanics that can transform our understanding of biology. Our pioneering solutions, ranging from PIUMA for large tissue characterization, to CHIARO and PAVONE for microscope-compatible and screening-scale analysis, and CUORE for automated contractility testing, embody our commitment to unlocking the power of mechanobiology. By enabling real-time and non-destructive mechanical characterization, our technology offers scientists unprecedented insights into the behavior of soft and living biomaterials—cells, hydrogels, spheroids, organoids, and tissues—in both healthy and diseased states.
This strategic capital infusion will accelerate the integration of our innovative systems into advanced laboratories globally, amplifying their impact on disease modeling, therapy development, and regenerative medicine. The funding is earmarked not only for scaling existing solutions but also for driving research and development of next-generation platforms that promise to further enhance the precision and efficiency of mechanical measurements. As the mechanics start the minute cells hit the wellplate, our technology ensures that each experiment is backed by robust, real-time data that can lead to groundbreaking discoveries. We are deeply grateful to our investors and partners for believing in our vision, and we look forward to advancing scientific research and improving patient outcomes through continued innovation in mechanobiology.
